EQT Partners AB is a private equity and venture capital firm based in Stockholm, Sweden, with a global presence through additional offices in major cities across Europe, Asia, and North America. Founded in 1994, EQT specializes in a wide array of investment strategies, including expansion capital, buyouts, and growth equity, focusing on medium to large-sized companies with consistent cash flows or significant intrinsic value. The firm targets various sectors, such as healthcare, technology, energy, and infrastructure, and emphasizes investments in mid-market situations, over-leveraged companies, and distressed assets. EQT's investment approach is characterized by taking controlling or co-controlling equity stakes in its portfolio companies and actively participating in their management, often securing board seats. The firm typically holds investments for four to eight years, aiming to enhance growth and create long-term value for stakeholders.
Unit 1507-1508 CITIC Square 1168, Nanjing Road West, Shanghai 200041, China
Andreas Aschenbrenner
Partner
Fouad Azzam
General Partner
Peter Balslev
Managing Director
Gregory Bernstein
Associate
Lennart Blecher
Deputy Managing Partner
Clemens van Blitterswijk
Founder of LSP Health Economics Fund
Carolina Brochado
Partner
Brian Chang
Partner
Hans Clevers
Venture Partner
Rudy Dekeyser
Co-Founder Managing Director
Johan Dettel
Partner
Christina Drews
COO and Executive Committee
Victor Englesson
Partner
Stephen Escudier
Partner
Andreas Fischer
Partner
Fabian Grone
Partner, Head of Asia
Andreas Huber
Partner
Lars Jörnow
Partner
Kasper Grundtvig Knokgaard
Partner
John de Koning
General Partner
Kees Koolen
Partner
Ulrich Kollensperger
Partner
Nicholas Macksey
Partner
Robert Maclean
Partner
Martin Mix
Managing Director
Joep Muijrers
General Partner
Jörg Neermann
Partner
Suzana Peric
Director
Anne Portwich
Partner
Johannes Reichel
Partner
Carl Johan Renstrom
Partner
Niklas Ringby
Partner
Darlene Sammon
Partner
Carlos Santana
Partner
Christian Sinding
Managing Partner and CEO
Jan Stypulkowski
Managing Director
Jan Vesely
Partner
Fabian Wasmus
Partner
Mark Wegter
Managing Partner
Matthias Wittkowski
Partner
Fredrik Atting
Partner
Past deals in Medical Devices
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
NUA Surgical
Series A in 2024
NUA Surgical is an innovative start-up located at the Innovation Hub in Galway, Ireland, focused on enhancing women's health through advanced medical devices. The company has developed a patented surgical retractor specifically designed to improve the safety and efficiency of cesarean deliveries. By concentrating on research and development, NUA Surgical aims to provide obstetricians with tools that facilitate superior surgical outcomes, ultimately making C-sections safer for patients.
Sequana Medical
Post in 2024
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
Asceneuron
Series C in 2024
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Binx
Series F in 2024
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.
Onera Health
Series C in 2024
Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.
AgomAb Therapeutics
Series C in 2023
AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.
Xeltis
Series D in 2023
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Xeltis
Series D in 2023
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Cardiac Dimensions
Series D in 2023
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
SHL Medical
Secondary Market in 2022
SHL Medical AG is a Swiss company based in Zug that specializes in designing, developing, and manufacturing advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989, the company serves pharmaceutical and biotechnology companies worldwide by providing comprehensive services that include final assembly, labeling, and packaging. In addition to its core focus on drug delivery systems, SHL Medical also offers contract manufacturing services and produces various medical products such as pressure mattress systems and patient lifting slings. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring it delivers innovative solutions tailored to the needs of its clients.
Vara
Series A in 2022
Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.
SPT Labtech
Acquisition in 2022
SPT Labtech specializes in designing and manufacturing automated instrumentation and consumables for life science research. Their product portfolio focuses on sample management, liquid handling, and multiplexed detection, which help to minimize assay volumes, enhance workflows, and reduce costs in fields such as drug discovery, structural biology, molecular biology, and genomics. By addressing existing customer challenges, SPT Labtech fosters innovation through its research and development efforts. The company prides itself on its deep application knowledge and engineering expertise, which allows it to support customers throughout the entire product lifecycle, from initial design to final manufacturing and sale. This comprehensive approach not only enhances productivity for life scientists but also strengthens client relationships through reliable technical and mechanical support.
ViCentra
Series C in 2021
ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.
Binx
Series E in 2021
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.
Cardiac Dimensions
Series C in 2020
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
ViCentra
Venture Round in 2020
ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.
Health Management International
Private Equity Round in 2020
Health Management International Ltd is a regional private healthcare provider operating in Singapore, Malaysia, and Indonesia. The company owns two tertiary hospitals in Malaysia and a healthcare training center in Singapore, along with a network of representative offices across the three countries. It specializes in delivering a range of medical services, including cardio-vascular care, digestive health, minimally invasive surgeries, and diagnostic services. By focusing on both local and international patients, Health Management International aims to enhance the accessibility and quality of healthcare in the region.
SHL Medical
Private Equity Round in 2020
SHL Medical AG is a Swiss company based in Zug that specializes in designing, developing, and manufacturing advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989, the company serves pharmaceutical and biotechnology companies worldwide by providing comprehensive services that include final assembly, labeling, and packaging. In addition to its core focus on drug delivery systems, SHL Medical also offers contract manufacturing services and produces various medical products such as pressure mattress systems and patient lifting slings. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring it delivers innovative solutions tailored to the needs of its clients.
Aldevron
Acquisition in 2019
Aldevron provides contract manufacturing and scientific services. It specializes in plasmid DNA, protein production, and antibody generation. It combines best-in-class products and service with the ideal operating environment to lay the groundwork for vital new discoveries worldwide. Its services include Plasmid DNA Production, Protein Production, Antibody Discovery, mRNA Production, and other related services. It was founded in 1998 and is headquartered in Fargo, North Dakota, United States.
WS Audiology
Acquisition in 2019
WS Audiology A/S was formed in 2019 through the partnership of Singapore-headquartered Sivantos and Lynge/Denmark-based Widex. Two pioneers joining forces with one clear ambition: to expand hearing care for the millions of people with hearing needs.
Atlantic Therapeutics Limited
Series B in 2019
Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.
Karo Healthcare
Acquisition in 2019
Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.
Zemax
Acquisition in 2018
Zemax, LLC specializes in developing software for optical and illumination design, catering to various industries including aerospace, defense, medical, and life sciences. Founded in 2014 and based in Kirkland, Washington, the company provides tools for designing projection lenses, binoculars, collimating lenses, laser lenses, and biomedical imaging systems. Zemax's software is recognized for its technical power, user-friendliness, and accuracy, enabling optical engineers to address a wide range of design challenges. In addition to its software offerings, Zemax also provides training and support services, enhancing the workflow and communication between optical and mechanical engineers to facilitate efficient and precise optical component design through physics-based optimization.
Simplify Medical
Series B in 2018
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.
Xeltis
Series C in 2017
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Clinical Innovations
Acquisition in 2017
Clinical Innovations is the largest healthcare manufacturer exclusively focused on labor and delivery. Already a market leader in several categories with products such as the Koala® Intrauterine Pressure Catheter and Kiwi® Vacuum-Assisted Delivery System, Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Since its inception in 1993, Clinical Innovations has consistently expanded its worldwide presence, becoming the market leader in several product categories. This growth has fueled the ability to invest in new product ideas where innovation makes the difference. And with a management team with extensive experience in the medical device industry, Clinical Innovations possesses the working knowledge to develop those new product ideas into industry-changing specialty devices. Clinical Innovations is dedicated to quality and customer service. With ISO13485 certification and strong relationships with top worldwide medical distributors, Clinical Innovations has the systems and infrastructure in place to promptly respond to market trends and customer suggestions. Clinical Innovations is a Prizker Group Company.
Simplify Medical
Series B in 2017
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.
Ottobock
Private Equity Round in 2017
Ottobock is a designer and manufacturer of prosthetic limbs dedicated to enhancing the mobility and quality of life for individuals with disabilities. The company focuses on innovative solutions, offering products such as a computerized knee that adapts its resistance to accommodate various walking gaits, and a fully articulated robotic hand prosthesis. These advancements enable users to overcome challenges associated with their disabilities, promoting independence and active lifestyles. Driven by a commitment to innovation and the desire to provide optimal support for those in need, Ottobock strives to improve the overall well-being of its customers.
Binx
Series D in 2017
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.
Rotation Medical
Series B in 2016
Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.
ViCentra
Series B in 2016
ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.
Xeltis
Series B in 2015
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Cardiac Dimensions
Series A in 2015
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
Xeltis
Series B in 2014
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Curetis
Series B in 2014
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Sivantos
Acquisition in 2014
We are one of the world’s top manufacturers of hearing aids. Sivantos Group companies serve hearing care professionals globally, and have built up market-leading positions in many countries. In fact we are proud to develop and manufacture one out of every four hearing aids being used worldwide. We have helped people with hearing loss for far more than 100 years. We offer hearing aids branded Siemens, Signia, Audio Service, Rexton and A&M. Complementary accessories, fitting software, smartphone apps and diagnostics workflow solutions are also part of our portfolio. Today, Sivantos Group employs about 5,000 people in more than 25 countries. They all do their best to help hearing impaired people to enjoy the sound of life.
Mint Solutions
Series A in 2014
Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.
Rotation Medical
Series B in 2014
Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.
Binx
Series B in 2014
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.
IlluminOss
Series C in 2012
IlluminOss Medical, Inc. is a commercial-stage medical device company that specializes in minimally invasive technology for fracture repair and stabilization. The company has developed a unique system that uses a light-curable polymer within an expandable balloon to create a patient-conforming intramedullary implant, facilitating effective bone stabilization. This innovative approach is particularly beneficial for patients with osteoporotic or compromised bone, providing a tailored solution for orthopedic challenges. The IlluminOss system is CE-marked and FDA-cleared for various anatomical sites, with additional indications under review. By focusing on the design and marketing of orthopedic fracture repair products, IlluminOss aims to offer clinicians a rapid and customized method for stabilizing bone fractures.
BSN medical
Acquisition in 2012
BSN medical is a global leader in the worldwide healthcare market specialising in the areas of Compression Therapy, Wound Care and Orthopaedics. We are focused on the development of world-class branded products that offer high quality solutions for our caregivers and patients. BSN medical connects its broad portfolio in Wound Care & related Vascular Diseases, Lymphology and non-invasive Orthopaedics with strong technological competencies to meet the market's need for reduced complexity and more efficient treatments. With a continuously developing unique and holistic network integrated therapy solutions, BSN medical consistently supports a continuum of care.
ATOS MEDICAL
Acquisition in 2011
Atos Medical, founded in 1986, specializes in manufacturing therapeutic devices aimed at enhancing the quality of life for laryngectomized patients. The company produces a range of products, including voice prosthetics, pulmonary rehabilitation devices, adhesives, laryngectomy tubes, and hands-free speaking devices. With its headquarters in Sweden, Atos Medical operates a state-of-the-art clean room and laboratory to support research and development. The company has established a significant international presence, with subsidiaries in multiple countries, including the USA, UK, Germany, Spain, the Netherlands, Belgium, Sweden, and Switzerland, along with exclusive distributors in around 60 countries.
Binx
Series B in 2011
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.
Mendor
Series B in 2011
Mendor is a Finnish company, committed to the design, development and marketing of advanced diabetes management products. Mendor has launched a revolutionary, discreet, easy to use, portable all-in-one blood glucose meter and web-based software application for the daily management of diabetes. Mendor has designed its products together with users and diabetes experts to address the needs of people with diabetes requiring regular blood glucose monitoring.
Sapiens Steering Brain Stimulation
Series A in 2011
Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.
Curetis
Series A in 2009
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
HTL-STREFA, Inc.
Acquisition in 2009
HTL-Strefa is the globally unrivalled, leading developer and provider of blood micro-sampling medical devices with a 44% global market share by volume in safety lancets, with a strong and growing global position in personal lancets and pen needles.
BMEYE
Series A in 2009
BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.
FlowCardia
Series C in 2007
FlowCardia, Inc. is a medical device company established in 2002, specializing in the design and development of catheter-based technologies aimed at overcoming chronic total occlusions (CTOs) in coronary and peripheral arteries. CTOs present significant challenges in interventional therapy, often resulting in patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia's innovative solutions seek to address this critical gap in treatment options, enhancing the safety and efficacy of procedures for patients with these difficult-to-treat conditions.
Isto Technologies
Series E in 2007
ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.
BMEYE
Series A in 2006
BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.
Palodex
Private Equity Round in 2005
Palodex is a manufacturer of dental imaging products.
HemoCue
Acquisition in 1999
HemoCue AB specializes in the development and production of medical diagnostic products aimed at point-of-care testing. The company offers innovative microcuvette diagnostic systems that provide lab-quality results for essential blood and urine tests, including measurements of hemoglobin, glucose, white blood cell count, and urine albumin. These tests are crucial for managing conditions such as anemia, malnutrition, diabetes, and infections. By enabling healthcare institutions to perform accurate and timely diagnostics at the point of care, HemoCue enhances the ability to monitor, detect, and evaluate various health conditions effectively. The company's focus on efficiency ensures that these vital tests can be conducted easily and quickly, making them accessible to a broader range of healthcare providers.
Pulnovo Medical
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.